Cross-source identity
National Provider Identifier 1104048446 as it appears in every federal dataset Fonteum holds. Each row is a distinct public source; the chip carries the source and the snapshot date behind that field — the record-level form of the source-provenanced graph.
| Federal source | Key | What it provides | Provenance |
|---|
| CMS NPPES | NPI 1104048446 | Registry identity — psychiatrist, taxonomy 2084P0800X | Source:CMS NPPESSnapshot 2026-05-06 |
| CMS Open Payments | NPI 1104048446 | 85 industry-payment records, 2024 | Source:CMS Open PaymentsSnapshot PY2024 |
| CMS Medicare Part D | NPI 1104048446 | 53 drugs prescribed, 2024 | Source:CMS Part DSnapshot DY2024 |
| Fonteum entity graph | entity 15e96712… | Canonical resolved node · 4 identifier(s) · 5 edge(s) | Source:Entity graphSnapshot 2026-06-11 |
Industry payments
Payments and transfers of value this clinician received from drug and device manufacturers, disclosed under the Physician Payments Sunshine Act. A payment is a disclosure, not a judgment.
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,750 | 5 |
| Food and Beverage | $2,197 | 79 |
| Education | $111 | 1 |
| Manufacturer | Amount | Records |
|---|---|---|
| Abbvie Inc. | $9,376 | 18 |
| Janssen Pharmaceuticals, Inc | $587 | 23 |
| Teva Pharmaceuticals Usa, Inc. | $221 |
Prescribing
Prescriptions written under Medicare Part D, aggregated by drug across the program. Totals reflect claims paid, not patients treated.
| Drug | Claims | Drug cost |
|---|---|---|
| Ingrezza(Valbenazine Tosylate) | 23 | $185,612 |
| Austedo Xr(Deutetrabenazine) | 18 | $89,008 |
| Invega Sustenna(Paliperidone Palmitate) | 16 | $33,666 |
| Rexulti(Brexpiprazole) | 12 | $17,261 |
| Effexor Xr(Venlafaxine Hcl) | 11 | $17,138 |
Beneficiary counts below 11 are suppressed by CMS — the total shown is a lower bound.
Quality
CMS Quality Payment Program Merit-based Incentive Payment System (MIPS) final score, where this clinician participated. Absence of a score is not a quality signal — many clinicians report through a group or are exempt.
Enrollment & sanctions
Screening aid — re-confirm any match against the issuing list before acting. A clean result means no record was found in the federal OIG LEIE or the state Medicaid lists Fonteum currently holds (NY, OH, GA), not a guarantee that none exists elsewhere. Not a legal or credentialing certification.
Ownership & affiliations
One-hop relationships in the resolved entity graph — chain membership, ownership, and operation edges, each backed by a federal source row. Most individual clinicians carry none; edges populate for owners and organizations as the Lane D backfill runs.
| Relationship | Entity | Source |
|---|---|---|
| ← pays | Janssen Pharmaceuticals, Inc (NJ) | cms_open_payments |
| ← pays | Neos Therapeutics, Lp (CO) | cms_open_payments |
| ← pays | Noven Therapeutics, Llc (FL) | cms_open_payments |
| ← pays | Novo Nordisk Inc (NJ) | cms_open_payments |
| ← pays | Abbvie Inc. (IL) | cms_open_payments |
| 7 |
| Iti, Inc. (D/B/A Intra-Cellular Therapies, Inc.) | $165 | 9 |
| Supernus Pharmaceuticals, Inc. | $134 | 6 |